Physician profile
William C Mcgarvey
NPI 1679544308
$3,506,890.06
in general payments reported to CMS, 2019-2025
30 companies · $843K in 2025
The $843K reported for 2025 was more than what 99% of Foot and Ankle Surgery providers received nationally (typical 2025 total: $1,200).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $35K · 2021: $407K · 2022: $537K · 2023: $780K · 2024: $869K · 2025: $843K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $2.2M · Consulting Fee: $296K · Travel and Lodging: $33K · Food and Beverage: $9,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $2,153,069.19 |
| Consulting Fee | $295,770.00 |
| Travel and Lodging | $33,451.10 |
| Food and Beverage | $9,067.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,384,481.50 | 2019-2025 | Invision, Infinity, Prophecy |
| Wright Medical Technology, INC. | $60,156.38 | 2019-2020 | |
| Extremity Medical | $51,722.78 | 2022-2025 | Io Fix, Lapidus, Joint Prep |
| Treace Medical Concepts, INC. | $3,570.83 | 2019-2025 | |
| Medinc of Texas | $1,811.63 | 2022-2025 | |
| Alafair Biosciences, INC. | $694.18 | 2023-2025 | Versawrap |
| Medshape, INC. | $510.39 | 2025 | Dynanail |
| Innovation Technologies INC | $402.74 | 2022-2024 | Irrisept |
| Zimmer Biomet Holdings, INC. | $380.91 | 2019-2022 | |
| Paragon 28, INC. | $342.72 | 2023-2025 | Apex 3d, Additive Orthopedics |
| Smith+Nephew, INC. | $341.02 | 2019-2025 | Versajet, Pico 14 |
| Linvatec Corporation | $322.98 | 2023-2025 | Biobrace 23mm, Allograft Tissue, Neospan |
| In2bones USA, LLC | $274.92 | 2021 | |
| Sanara Medtech INC. | $209.94 | 2025 | Celleraterx |
| Restor3d, INC. | $208.62 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ossio INC | $198.31 | 2021 | |
| Depuy Synthes Sales INC. | $185.16 | 2021-2025 | Va-Lcp |
| Trilliant Surgical LLC. | $141.03 | 2023 | Arsenal Ankle 10 Hole 1/3 Tubular Plate |
| Arthrex, INC. | $140.37 | 2019 | |
| Nevro Corp. | $129.86 | 2023 | Senza |
| Bone Support INC. | $115.71 | 2021 | |
| Exactech, INC. | $109.97 | 2022 | |
| Amgen INC. | $97.79 | 2025 | |
| Medline Industries Lp | $91.43 | 2025 | |
| Voom Medical Devices, INC. | $88.63 | 2025 | Revcon Instrument Kit, Sterile |
| Osteocentric Technologies, INC. | $56.88 | 2020 | |
| Kerecis Limited | $36.46 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Ossur Americas, INC. | $28.00 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $20.65 | 2025 | |
| Urgo Medical North America, LLC | $18.27 | 2023 | Urgok2, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,646.93 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$1,666.68 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcgarvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.